Compile Data Set for Download or QSAR
Report error Found 71 Enz. Inhib. hit(s) with all data for entry = 9518
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1 [L188C](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472683(N-(5-(4-methylpiperazin-1- yl)pyridin-2-yl)-8',9'-...)
Affinity DataIC50: 1.80E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1 [L188C](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472681(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.80E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472683(N-(5-(4-methylpiperazin-1- yl)pyridin-2-yl)-8',9'-...)
Affinity DataIC50: 2.60E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1 [L188C](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472682(ethyl 2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)...)
Affinity DataIC50: 3.50E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472682(ethyl 2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)...)
Affinity DataIC50: 4.10E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472681(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 4.70E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472673(10,10-dimethyl-2-((5-(4- methylpiperazin-1-yl)pyri...)
Affinity DataIC50: 8.06E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472680(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.44E+4nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1 [L188C](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472673(10,10-dimethyl-2-((5-(4- methylpiperazin-1-yl)pyri...)
Affinity DataIC50: 3.06E+4nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472677(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 4.77E+4nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1 [L188C](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472680(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 5.04E+4nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1 [L188C](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472677(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 7.59E+4nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472677(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 8.64E+4nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472678(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472678(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472677(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM472677(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472677(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472675(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM472675(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472675(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472674(10,10-dimethyl-2-((5-(4- methylpiperazin-1-yl)pyri...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472674(10,10-dimethyl-2-((5-(4- methylpiperazin-1-yl)pyri...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472673(10,10-dimethyl-2-((5-(4- methylpiperazin-1-yl)pyri...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM472673(10,10-dimethyl-2-((5-(4- methylpiperazin-1-yl)pyri...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472673(10,10-dimethyl-2-((5-(4- methylpiperazin-1-yl)pyri...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472683(N-(5-(4-methylpiperazin-1- yl)pyridin-2-yl)-8',9'-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472683(N-(5-(4-methylpiperazin-1- yl)pyridin-2-yl)-8',9'-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM472678(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472673(10,10-dimethyl-2-((5-(4- methylpiperazin-1-yl)pyri...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472680(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM472680(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472680(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472681(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM472681(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472681(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472682(ethyl 2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM472682(ethyl 2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472682(ethyl 2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472683(N-(5-(4-methylpiperazin-1- yl)pyridin-2-yl)-8',9'-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM472683(N-(5-(4-methylpiperazin-1- yl)pyridin-2-yl)-8',9'-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472683(N-(5-(4-methylpiperazin-1- yl)pyridin-2-yl)-8',9'-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472680(2-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472675(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1 [L188C](Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472675(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472675(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472675(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472675(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472677(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM472677(2'-((5-(4-methylpiperazin-1- yl)pyridin-2-yl)amino...)
Affinity DataIC50: 1.00E+5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 71 total ) | Next | Last >>
Jump to: